State Street Corp Buys 11,566 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

State Street Corp lifted its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 0.7% in the third quarter, Holdings Channel.com reports. The firm owned 1,733,486 shares of the company’s stock after purchasing an additional 11,566 shares during the quarter. State Street Corp’s holdings in Atea Pharmaceuticals were worth $5,807,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. BML Capital Management LLC increased its stake in shares of Atea Pharmaceuticals by 4.3% in the third quarter. BML Capital Management LLC now owns 6,650,000 shares of the company’s stock worth $22,278,000 after buying an additional 274,379 shares during the period. FMR LLC grew its stake in Atea Pharmaceuticals by 2.8% in the third quarter. FMR LLC now owns 6,618,297 shares of the company’s stock worth $22,171,000 after purchasing an additional 182,174 shares during the period. Almitas Capital LLC purchased a new position in Atea Pharmaceuticals during the 2nd quarter valued at about $4,271,000. Renaissance Technologies LLC boosted its position in shares of Atea Pharmaceuticals by 1.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,141,500 shares of the company’s stock worth $3,778,000 after purchasing an additional 18,100 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Atea Pharmaceuticals by 8.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 650,157 shares of the company’s stock worth $2,178,000 after purchasing an additional 50,794 shares during the last quarter. 86.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Atea Pharmaceuticals

In related news, Director Franklin M. Berger sold 359,606 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the sale, the director now directly owns 451,897 shares of the company’s stock, valued at approximately $1,287,906.45. This trade represents a 44.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 17.80% of the stock is currently owned by company insiders.

Atea Pharmaceuticals Trading Up 1.2 %

Shares of AVIR opened at $3.33 on Friday. Atea Pharmaceuticals, Inc. has a 12 month low of $2.75 and a 12 month high of $4.60. The business’s fifty day simple moving average is $3.28 and its two-hundred day simple moving average is $3.48. The company has a market cap of $281.26 million, a price-to-earnings ratio of -1.61 and a beta of 0.20.

Atea Pharmaceuticals (NASDAQ:AVIR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.13. During the same period in the previous year, the business earned ($0.40) earnings per share. As a group, research analysts forecast that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.